GlassScriptPhysician profile
David A Peyser
NPI 1194075887
$2,794.14
in general payments reported to CMS, 2019-2025
20 companies · $984 in 2025
The $984 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $339 · 2024: $1,471 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $540.26 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $350.16 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Silk Road Medical, INC. | $321.58 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Lilly USA, LLC | $257.83 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $242.48 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $241.05 | 2024 | Tremfya |
| Abbvie INC. | $234.57 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.84 | 2025 | |
| Amgen INC. | $88.79 | 2024-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $76.21 | 2023-2025 | Verquvo, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $51.48 | 2023 | Rexulti |
| Exact Sciences Corporation | $51.32 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $46.02 | 2025 | Symbravo |
| Inspire Medical Systems, INC. | $35.68 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2025 | Vpriv |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.56 | 2025 | |
| Sanofi Pasteur INC. | $20.25 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.85 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $19.80 | 2025 | Flucelvax, Fluad |
| Genzyme Corporation | $13.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Peyser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.